Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083.

Published

Journal Article

BACKGROUND: Increasing the breadth of human immunodeficiency virus type 1 (HIV-1) vaccine-elicited immune responses or targeting conserved regions may improve coverage of circulating strains. HIV Vaccine Trials Network 083 tested whether cellular immune responses with these features are induced by prime-boost strategies, using heterologous vectors, heterologous inserts, or a combination of both. METHODS: A total of 180 participants were randomly assigned to receive combinations of adenovirus vectors (Ad5 or Ad35) and HIV-1 envelope (Env) gene inserts (clade A or B) in a prime-boost regimen. RESULTS: T-cell responses to heterologous and homologous insert regimens targeted a similar number of epitopes (ratio of means, 1.0; 95% confidence interval [CI], .6-1.6; P = .91), but heterologous insert regimens induced significantly more epitopes that were shared between EnvA and EnvB than homologous insert regimens (ratio of means, 2.7; 95% CI, 1.2-5.7; P = .01). Participants in the heterologous versus homologous insert groups had T-cell responses that targeted epitopes with greater evolutionary conservation (mean entropy [±SD], 0.32 ± 0.1 bits; P = .003), and epitopes recognized by responders provided higher coverage (49%; P = .035). Heterologous vector regimens had higher numbers of total, EnvA, and EnvB epitopes than homologous vector regimens (P = .02, .044, and .045, respectively). CONCLUSIONS: These data demonstrate that vaccination with heterologous insert prime boosting increased T-cell responses to shared epitopes, while heterologous vector prime boosting increased the number of T-cell epitopes recognized. CLINICAL TRIALS REGISTRATION: NCT01095224.

Full Text

Duke Authors

Cited Authors

  • Walsh, SR; Moodie, Z; Fiore-Gartland, AJ; Morgan, C; Wilck, MB; Hammer, SM; Buchbinder, SP; Kalams, SA; Goepfert, PA; Mulligan, MJ; Keefer, MC; Baden, LR; Swann, EM; Grant, S; Ahmed, H; Li, F; Hertz, T; Self, SG; Friedrich, D; Frahm, N; Liao, H-X; Montefiori, DC; Tomaras, GD; McElrath, MJ; Hural, J; Graham, BS; Jin, X; HVTN 083 Study Group and the NIAID HVTN,

Published Date

  • February 15, 2016

Published In

Volume / Issue

  • 213 / 4

Start / End Page

  • 541 - 550

PubMed ID

  • 26475930

Pubmed Central ID

  • 26475930

Electronic International Standard Serial Number (EISSN)

  • 1537-6613

Digital Object Identifier (DOI)

  • 10.1093/infdis/jiv496

Language

  • eng

Conference Location

  • United States